Fig. 6: Targeting TACC3 inhibits tumor growth in centrosome-amplified breast tumors in vivo. | Cell Death & Differentiation

Fig. 6: Targeting TACC3 inhibits tumor growth in centrosome-amplified breast tumors in vivo.

From: Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification

Fig. 6

A Western blot validation of CRISPR/Cas9-mediated knockout of TACC3 in MDA-MB-231 cells. B–E The effect of TACC3 knockout on colony formation in JIMT-1 (B, C) and MDA-MB-231 (D, E) cells. F Relative colony formation ability of MCF12A cells overexpressing different regions of TACC3. 1-838: full length, 1-593: N-terminus, 594-838; C-terminus. G–I Tumor growth (G) in xenografts of JIMT-1 sgCtrl vs. sgTACC3 cells, and the tumor weights and representative images at the end of the experiment (H, I). J–L Tumor growth (J) in xenografts of MDA-MB-231 sgCtrl vs. sgTACC3 cells, and the tumor weights and representative images at the end of the experiment (K, L). M Western blot analysis of TACC3, mitotic progression and G1/S progression markers, CDK inhibitor and apoptosis in MDA-MB-231 xenografts from J. N IF staining of TACC3 (magenta), α- (green) and γ- (red) tubulin in MDA-MB-231 xenografts from J. Scale bar = 40 µm for TACC3 and 20 µm α- and γ-tubulin. O Quantification of multipolar mitosis in MDA-MB-231 xenografts from J. P Tumor growth in xenografts of MDA-MB-231 cells treated with 75 mg/kg BO-264, twice daily (p.o.). Q, R The tumor weights (Q) and representative images (R) from vehicle vs. BO-264 treated mice from P at the end of the experiment. S Tumor growth of TNBC PDXs, TM01278 treated with 75 mg/kg BO-264, twice daily (p.o.). T, U The tumor weights (T) and representative images (U) from vehicle vs. BO-264 treated mice from S in the end of the experiment.

Back to article page